22:22 , Mar 18, 2019 |  BC Extra  |  Company News

Astellas adds more drug delivery tech via NapaJen deal

Astellas has completed a second deal for a drug delivery technology, this time with NapaJen, that stands to add a new modality to its pipeline. Astellas Pharma Inc. (Tokyo:4503) will use oligonucleotide delivery technology from...
14:36 , Mar 5, 2019 |  BC Extra  |  Financial News

First close for Seventure's new microbiome fund

Seventure Partners announced the first close of its second microbiome-focused health fund and is targeting a €200 million ($226.9 million) final raise. Seventure's Isabelle de Cremoux said the VC has raised more than half of...
17:43 , Oct 24, 2018 |  BC Week In Review  |  Company News

Anaeropharma and Chugai partner to discover cancer drugs using anaerobic bacteria

Anaeropharma Science Inc. (Tokyo, Japan) and Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) partnered to conduct joint research to discover cancer treatments using Anaeropharma's in situ Delivery and Production System (i-DPS) platform. i-DPS modifies anaerobic bacteria Bifidobacterium...
23:20 , Mar 1, 2018 |  BC Innovations  |  Targets & Mechanisms

Checking out the microbiome

What started out as a potential use in stratifying patients is growing into a new avenue for turning non-responders to responders, as evidence continues to emerge linking the microbiome to immuno-oncology. While the data are...
20:40 , Jul 7, 2017 |  BC Week In Review  |  Financial News

Anaeropharma raises $13.2M

Microbiome and cancer play Anaeropharma Science Inc. (Tokyo, Japan) raised $13.2 million on July 5 from new investors Novartis AG (NYSE:NVS; SIX:NOVN), Shinsei Corporate Investment and Seventure Partners’ Health for Life Capital. Existing investors Innovation...
19:01 , Jul 5, 2017 |  BC Extra  |  Financial News

Microbiome company Anaeropharma raises $13.2M

Microbiome and cancer play Anaeropharma Science Inc. (Tokyo, Japan) raised $13.2 million from new investors Novartis AG (NYSE:NVS; SIX:NOVN), Shinsei Corporate Investment and Seventure Partners’ Health for Life Capital. Existing investors Innovation Network Corp. of...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

APS001F: Phase I/II started

Anaeropharma began a dose-escalation, U.S. Phase I/II trial to evaluate IV APS001F given on days 1-3 of a 28-day cycle in combination with oral 5-flucytosine in about 75 patients. Anaeropharma Science Inc. , Tokyo, Japan...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Financial News

Anaeropharma Science proposes venture financing

Anaeropharma Science Inc. , Tokyo, Japan   Business: Cancer   Date announced: 02/23/12   Type: Venture financing   To be raised: Up to ¥2.2 billion ($27.7 million)   Investor: Innovation Network Corp. of Japan  ...
00:33 , Feb 25, 2012 |  BC Extra  |  Financial News

Anaeropharma to raise up to $27.7 million

Anaeropharma Science Inc. (Tokyo, Japan) said it plans to raise up to Y2.2 billion ($27.7 million) from Innovation Network Corp. of Japan (INCJ). INCJ made an initial Y700 million ($8.8 million) investment in November 2010....
07:00 , Oct 11, 2010 |  BC Week In Review  |  Company News

Anaeropharma Science, Eisai deal

Eisai received an option to license rights to Anaeropharma's APS001. Eisai received the right of first review of the Phase I results for the recombinant Bifidobacterium longum bacteria that has been modified to expresses the...